MX2024013890A - Vectores virales adeno-asociados que se dirigen a estructuras profundas del cerebro - Google Patents
Vectores virales adeno-asociados que se dirigen a estructuras profundas del cerebroInfo
- Publication number
- MX2024013890A MX2024013890A MX2024013890A MX2024013890A MX2024013890A MX 2024013890 A MX2024013890 A MX 2024013890A MX 2024013890 A MX2024013890 A MX 2024013890A MX 2024013890 A MX2024013890 A MX 2024013890A MX 2024013890 A MX2024013890 A MX 2024013890A
- Authority
- MX
- Mexico
- Prior art keywords
- adeno
- viral vectors
- targeting
- deep brain
- associated viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340823P | 2022-05-11 | 2022-05-11 | |
| US202263342324P | 2022-05-16 | 2022-05-16 | |
| PCT/US2023/021905 WO2023220287A1 (en) | 2022-05-11 | 2023-05-11 | Adeno-associated viral vectors for targeting deep brain structures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013890A true MX2024013890A (es) | 2025-03-07 |
Family
ID=88730946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013890A MX2024013890A (es) | 2022-05-11 | 2024-11-08 | Vectores virales adeno-asociados que se dirigen a estructuras profundas del cerebro |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260183425A1 (enExample) |
| EP (1) | EP4522272A4 (enExample) |
| JP (1) | JP2025516583A (enExample) |
| KR (1) | KR20250031153A (enExample) |
| CN (1) | CN119654334A (enExample) |
| AU (1) | AU2023269646A1 (enExample) |
| CA (1) | CA3252951A1 (enExample) |
| CO (1) | CO2024016255A2 (enExample) |
| IL (1) | IL316908A (enExample) |
| MX (1) | MX2024013890A (enExample) |
| WO (1) | WO2023220287A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4570260A1 (en) * | 2023-12-14 | 2025-06-18 | Medizinische Hochschule Hannover | Viral vector for transduction of adipocytes |
| WO2025231406A1 (en) * | 2024-05-02 | 2025-11-06 | The Children's Hospital Of Philadelphia | Methods to increase transduction of ependyma cells in brain |
| WO2025231387A1 (en) * | 2024-05-02 | 2025-11-06 | The Children's Hospital Of Philadelphia | Globus pallidus route of administration for deep brain gene therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6342886B2 (ja) * | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| SI3645551T1 (sl) * | 2017-06-27 | 2024-06-28 | Regeneron Pharmaceuticals, Inc. | S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice |
| US20220096574A1 (en) * | 2019-01-29 | 2022-03-31 | Holobiome, Inc. | Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis |
| TW202111127A (zh) * | 2019-07-24 | 2021-03-16 | 美商航海家醫療公司 | 用於治療亨丁頓舞蹈症之組合物及方法 |
| WO2021025995A1 (en) * | 2019-08-02 | 2021-02-11 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| CN115023242B (zh) * | 2019-11-22 | 2025-03-14 | 费城儿童医院 | 腺相关病毒载体变体 |
-
2023
- 2023-05-11 EP EP23804269.1A patent/EP4522272A4/en active Pending
- 2023-05-11 WO PCT/US2023/021905 patent/WO2023220287A1/en not_active Ceased
- 2023-05-11 CN CN202380045864.2A patent/CN119654334A/zh active Pending
- 2023-05-11 JP JP2024566316A patent/JP2025516583A/ja active Pending
- 2023-05-11 IL IL316908A patent/IL316908A/en unknown
- 2023-05-11 AU AU2023269646A patent/AU2023269646A1/en active Pending
- 2023-05-11 US US18/863,862 patent/US20260183425A1/en active Pending
- 2023-05-11 CA CA3252951A patent/CA3252951A1/en active Pending
- 2023-05-11 KR KR1020247040677A patent/KR20250031153A/ko active Pending
-
2024
- 2024-11-08 MX MX2024013890A patent/MX2024013890A/es unknown
- 2024-11-28 CO CONC2024/0016255A patent/CO2024016255A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250031153A (ko) | 2025-03-06 |
| US20260183425A1 (en) | 2026-07-02 |
| CN119654334A (zh) | 2025-03-18 |
| WO2023220287A1 (en) | 2023-11-16 |
| EP4522272A1 (en) | 2025-03-19 |
| AU2023269646A1 (en) | 2024-12-05 |
| CO2024016255A2 (es) | 2024-12-09 |
| IL316908A (en) | 2025-01-01 |
| JP2025516583A (ja) | 2025-05-30 |
| CA3252951A1 (en) | 2023-11-16 |
| EP4522272A4 (en) | 2026-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006188A (es) | Variantes del vector viral adenoasociado. | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| CL2021001278A1 (es) | Vesículas extracelulares modificadas y sus usos | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| MX2020007046A (es) | Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales. | |
| CY1121953T1 (el) | Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων | |
| CL2020001070A1 (es) | Composiciones de péptidos tau fosforilados y sus usos. | |
| CL2018001107A1 (es) | Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis. | |
| CO2019002239A2 (es) | Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| MX2019005879A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
| MX2021014789A (es) | Vectores aav con el promotor de la proteina cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las celulas de schwann como la enfermedad de charcot-marie-tooth. | |
| PE20220164A1 (es) | Vectores viricos y uso de los mismos en terapias celulares adoptivas | |
| MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
| PY19107677A (es) | Recinto urbano de espectáculos para proporcionar actividades de entretenimiento a una audiencia en un entorno temático de playa | |
| PE20180241A1 (es) | Adenovirus oncolitico que codifica una proteina b7 | |
| MX2019008755A (es) | Variantes de hsd17b13 y usos de las mismas. | |
| CR20170406A (es) | Arni variante | |
| CR20170139A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| MX2016012893A (es) | Sustancias terapéuticas combinadas supramoleculares. | |
| AR105080A1 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| MX2016009295A (es) | Cromatografia esteril y procesos de fabricacion. | |
| CO6731074A2 (es) | Composición vacunal para el control de las infestaciones por ectoparásitos | |
| CO2021015405A2 (es) | Expresión de proteínas de unión a antígenos en el sistema nervioso |